

# Daniele Calistri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4820083/publications.pdf>

Version: 2024-02-01

106  
papers

2,839  
citations

159358

30  
h-index

197535

49  
g-index

107  
all docs

107  
docs citations

107  
times ranked

5226  
citing authors

#	ARTICLE	IF	CITATIONS
1	High grade B-cell lymphoma with <i>MYC</i> , <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1356-1362.	0.6	2
2	Case Report: A BRCA2 Mutation Identified Through Next-Generation Sequencing in a Birt-Hogg-Dub Syndrome Family. <i>Frontiers in Oncology</i> , 2022, 12, 835346.	1.3	1
3	Endometrioid Cancer Associated With Endometriosis: From the Seed and Soil Theory to Clinical Practice. <i>Frontiers in Oncology</i> , 2022, 12, 859510.	1.3	5
4	Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 2352.	1.7	2
5	Rearrangements of <i>ATP5L</i> and <i>KMT2A</i> in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 192, e139-e144.	1.2	3
6	Genetic and Epigenetic Alterations of <i>CDH1</i> Regulatory Regions in Hereditary and Sporadic Gastric Cancer. <i>Pharmaceuticals</i> , 2021, 14, 457.	1.7	12
7	Circulating androgen receptor gene amplification and resistance to <sup>177</sup> Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. <i>British Journal of Cancer</i> , 2021, 125, 1226-1232.	2.9	13
8	Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance. <i>Cancers</i> , 2021, 13, 4515.	1.7	6
9	Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience. <i>Biomedicines</i> , 2021, 9, 1299.	1.4	10
10	Droplet Digital PCR for BCR-ABL1 Monitoring in Diagnostic Routine: Ready to Start?. <i>Cancers</i> , 2021, 13, 5470.	1.7	9
11	Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients. <i>Diagnostics</i> , 2020, 10, 269.	1.3	14
12	Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3532.	1.8	5
13	Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	3
14	The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases. <i>Cancers</i> , 2020, 12, 292.	1.7	11
15	<i>CDKN1A</i> upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells. <i>International Journal of Oncology</i> , 2020, 56, 1574-1584.	1.4	19
16	Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. <i>Oncology Reports</i> , 2020, 44, 1561-1573.	1.2	4
17	Identification of a novel large <i>EPCAM</i> - <i>MSH2</i> duplication, concurrently with LOHs in chromosome 20 and X, in a family with Lynch syndrome. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1999-2002.	1.0	0
18	E-cadherin Downregulation and microRNAs in Sporadic Intestinal-Type Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4452.	1.8	17

#	ARTICLE	IF	CITATIONS
19	Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition. <i>Cancers</i> , 2019, 11, 1340.	1.7	19
20	Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma. <i>Cells</i> , 2019, 8, 514.	1.8	13
21	Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy. <i>International Journal of Cancer</i> , 2019, 145, 390-400.	2.3	40
22	A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2092-2092.	0.6	4
23	Detection of a <i>CDH1</i> Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	0
24	A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy. <i>Breast</i> , 2018, 38, 92-97.	0.9	23
25	Stool DNA Integrity Method for Colorectal Cancer Detection. <i>Methods in Molecular Biology</i> , 2018, 1765, 193-202.	0.4	0
26	Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR). <i>Journal of Thoracic Disease</i> , 2018, 10, 4858-4864.	0.6	2
27	Contribution of MLYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy. <i>Frontiers in Oncology</i> , 2018, 8, 583.	1.3	25
28	Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 307.	1.8	56
29	Carcinosarcoma of the prostate: case report with molecular and histological characterization. <i>International Journal of Biological Markers</i> , 2018, 33, 540-544.	0.7	12
30	P3.02b-006 Role of TP53 Mutations in Determining Primary Resistance to First-Line Tyrosine Kinase Inhibitors in EGFR-Mutated NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1188-S1189.	0.5	0
31	Cell-Free DNA Integrity Analysis in Urine Samples. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	13
32	Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. <i>Neoplasia</i> , 2017, 19, 637-648.	2.3	81
33	Impact of <i>TP53</i> Mutations on Outcome in <i>EGFR</i> -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 2195-2202.	3.2	208
34	Serum and Plasma Copy Number Detection Using Real-time PCR. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	3
35	Right- versus left-side metastatic colorectal cancer: Differences in tumor biology and bevacizumab efficacy. <i>Annals of Oncology</i> , 2017, 28, iii8.	0.6	0
36	Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1240.	1.8	38

#	ARTICLE	IF	CITATIONS
37	Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. <i>Oncotarget</i> , 2017, 8, 47064-47075.	0.8	68
38	Cell-free DNA detected by liquid biopsy as a potential prognostic biomarker in early breast cancer. <i>Oncotarget</i> , 2017, 8, 16642-16649.	0.8	29
39	What influences preneoplastic colorectal lesion recurrence?. <i>Oncotarget</i> , 2017, 8, 12406-12416.	0.8	8
40	Digital PCR identifies changes in CDH1 (E-cadherin) transcription pattern in intestinal-type gastric cancer. <i>Oncotarget</i> , 2017, 8, 18811-18820.	0.8	6
41	BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype. <i>Oncotarget</i> , 2017, 8, 22640-22648.	0.8	10
42	miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 2735.	1.0	21
43	<i>GSTP1</i> Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications. <i>Disease Markers</i> , 2016, 2016, 1-6.	0.6	68
44	Cell-free DNA as a diagnostic marker for cancer: current insights. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6549-6559.	1.0	104
45	ALKtranslocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA. <i>Cytopathology</i> , 2016, 27, 103-107.	0.4	22
46	Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach. <i>Journal of Translational Medicine</i> , 2016, 14, 249.	1.8	16
47	Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 128, 333-339.	1.4	52
48	The potential use of urine cell free DNA as a marker for cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1283-1290.	1.5	39
49	Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 1-12.	1.6	5
50	Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman. <i>Lung Cancer</i> , 2016, 96, 52-55.	0.9	8
51	Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. <i>Clinical Lung Cancer</i> , 2016, 17, 384-390.	1.1	77
52	Circulating <i>AR</i> copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 37839-37845.	0.8	69
53	Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients. <i>Disease Markers</i> , 2015, 2015, 1-6.	0.6	40
54	eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. <i>Journal of Translational Medicine</i> , 2015, 13, 258.	1.8	33

#	ARTICLE	IF	CITATIONS
55	EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab. <i>Oncology Letters</i> , 2015, 9, 1432-1438.	0.8	3
56	Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?. <i>International Journal of Molecular Sciences</i> , 2015, 16, 747-757.	1.8	28
57	Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. <i>British Journal of Cancer</i> , 2015, 112, 1717-1724.	2.9	112
58	Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results. <i>Drugs</i> , 2015, 75, 1757-1771.	4.9	11
59	Discrepancies between VEGF $\hat{\sim}$ 1154 G&gt;A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue. <i>International Journal of Molecular Sciences</i> , 2014, 15, 13333-13343.	1.8	10
60	Copy Number Analysis of 24 Oncogenes: MDM4 Identified as a Putative Marker for Low Recurrence Risk in Non Muscle Invasive Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2014, 15, 12458-12468.	1.8	13
61	Clinical and Genetic Factors Related to Cancer-Induced Bone Pain and Bone Pain Relief. <i>Oncologist</i> , 2014, 19, 1276-1283.	1.9	9
62	Assessment of DNA Damage and Telomerase Activity in Exfoliated Urinary Cells as Sensitive and Noninvasive Biomarkers for Early Diagnosis of Bladder Cancer in Ex-Workers of a Rubber Tyres Industry. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	12
63	First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer. <i>BMC Cancer</i> , 2014, 14, 478.	1.1	12
64	Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 65.	3.5	14
65	Improved Stool DNA Integrity Method for Early Colorectal Cancer Diagnosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2553-2560.	1.1	12
66	Circulating and stool nucleic acid analysis for colorectal cancer diagnosis. <i>World Journal of Gastroenterology</i> , 2014, 20, 957.	1.4	32
67	DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 94.	3.5	47
68	Urine Cell-Free DNA integrity as a marker for early bladder cancer diagnosis: Preliminary data. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1744-1750.	0.8	69
69	Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. <i>Molecular and Clinical Oncology</i> , 2013, 1, 575-581.	0.4	42
70	Urine Cell-Free DNA Integrity as a Marker for Early Prostate Cancer Diagnosis: A Pilot Study. <i>BioMed Research International</i> , 2013, 2013, 1-5.	0.9	48
71	Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue. <i>Journal of Clinical Pathology</i> , 2013, 66, 708-710.	1.0	11
72	Gene methylation in rectal cancer: Predictive marker of response to chemoradiotherapy?. <i>Journal of Cellular Physiology</i> , 2013, 228, 2343-2349.	2.0	30

#	ARTICLE	IF	CITATIONS
73	PI-PLC $\gamma$ 21 gene copy number alterations in breast cancer. <i>Oncology Reports</i> , 2012, 27, 403-8.	1.2	9
74	<i>EGFR</i>and<i>K-ras</i>mutations in cytologic samples from fine-needle aspirates in NSCLC patients: Table 1â€œ. <i>European Respiratory Journal</i> , 2012, 40, 267-269.	3.1	13
75	Characterization of Molecular Alterations of BRCA1/2: Analysis and Interpretation Guidelines. <i>Current Women's Health Reviews</i> , 2012, 8, 4-11.	0.1	0
76	LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation. <i>Oncology Reports</i> , 2012, 28, 2271-2277.	1.2	7
77	Urinary biomarkers of non-muscle-invasive bladder cancer: current status and future potential. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 743-752.	1.1	9
78	Specific Biomarkers Are Associated with Docetaxel and Gemcitabine-Resistant NSCLC Cell Lines. <i>Translational Oncology</i> , 2012, 5, 461-468.	1.7	25
79	Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study. <i>Journal of Translational Medicine</i> , 2012, 10, 87.	1.8	37
80	Bone metastases detection by circulating biomarkers: OPG and RANK-L. <i>International Journal of Oncology</i> , 2011, 39, 255-61.	1.4	11
81	Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study. <i>Radiation Oncology</i> , 2011, 6, 161.	1.2	21
82	Combining cytology, TRAP assay, and FISH analysis for the detection of bladder cancer in symptomatic patients. <i>Annals of Oncology</i> , 2011, 22, 2294-2298.	0.6	22
83	Fecal DNA for Noninvasive Diagnosis of Colorectal Cancer in Immunochemical Fecal Occult Blood Testâ€œPositive Individuals. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2647-2654.	1.1	24
84	Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients. <i>International Journal of Biological Markers</i> , 2009, 24, 253-257.	0.7	9
85	Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer. <i>Cellular Oncology</i> , 2009, 31, 11-7.	1.9	13
86	The current role of telomerase in the diagnosis of bladder cancer. <i>Indian Journal of Urology</i> , 2009, 25, 40.	0.2	11
87	The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. <i>International Journal of Biological Markers</i> , 2009, 24, 119-129.	0.7	6
88	Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients. <i>International Journal of Biological Markers</i> , 2009, 24, 253-257.	0.7	9
89	Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 343-349.	1.1	7
90	Disease family history and modification of breast cancer risk in common BRCA2 variants. <i>Oncology Reports</i> , 2008, 19, 783-6.	1.2	9

#	ARTICLE	IF	CITATIONS
91	Urine Telomerase Activity for the Detection of Bladder Cancer in Females. <i>Journal of Urology</i> , 2007, 178, 57-61.	0.2	28
92	p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. <i>Journal of Cellular Physiology</i> , 2006, 206, 611-615.	2.0	66
93	RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients. <i>Annals of Oncology</i> , 2006, 17, 424-428.	0.6	31
94	Urine Telomerase and Bladder Cancer Detection—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 998.	3.8	1
95	Free DNA and Carcinoembryonic Antigen Serum Levels: An Important Combination for Diagnosis of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 6985-6988.	3.2	115
96	Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. <i>Journal of Cellular Physiology</i> , 2005, 204, 484-488.	2.0	79
97	Relevance of Urine Telomerase in the Diagnosis of Bladder Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2052.	3.8	99
98	Development and characterization of a monoclonal antibody directed against human telomerase reverse transcriptase (hTERT). <i>Journal of Biotechnology</i> , 2005, 118, 370-378.	1.9	9
99	c-kit and SCF Expression in Normal and Tumor Breast Tissue. <i>Breast Cancer Research and Treatment</i> , 2004, 83, 33-42.	1.1	61
100	Urine Telomerase: An Important Marker in the Diagnosis of Bladder Cancer. <i>Neoplasia</i> , 2004, 6, 234-239.	2.3	37
101	Detection of Colorectal Cancer by a Quantitative Fluorescence Determination of DNA Amplification in Stool. <i>Neoplasia</i> , 2004, 6, 536-540.	2.3	21
102	Fecal multiple molecular tests to detect colorectal cancer in stool. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 377-383.	2.4	81
103	Population-based screening for hereditary breast cancer in a region of North-Central Italy. <i>International Journal of Molecular Medicine</i> , 2002, 10, 299-305.	1.8	1
104	Telomerase Activity Detected by Quantitative Assay in Bladder Carcinoma and Exfoliated Cells in Urine. <i>Neoplasia</i> , 2001, 3, 446-450.	2.3	25
105	Detection of germline BRCA1 mutations by Multiple-Dye Cleavase Fragment Length Polymorphism (MD-CFLP) method. <i>British Journal of Cancer</i> , 2001, 85, 845-849.	2.9	4
106	Microsatellite instability and mutations of p53 and TGF- $\beta$ RII genes in gastric cancer. <i>Human Genetics</i> , 1996, 98, 601-607.	1.8	75